Aethlon Medical, Inc.

AEMD Healthcare Medical Devices

Aethlon Medical, Inc.’s revenue for fiscal 2023 (year ended March 2023) was $574,200.00, up 95.2% from fiscal 2022.

EPS
+90.5%
Free cash flow
−11.1%

Quarter to June 2026, against a year earlier

5.47 0.16 +3.01%
Market cap
$8.5M
P/E
0.0×
Fwd P/E
−0.3×
Dividend yield
—
F-score
5/9
Altman Z
−10.75
Beneish M
n/a
Dividend safety
n/a

Aethlon Medical, Inc. (AEMD) EV/Sales

Alert me on EV/Sales

As of 6 November 2026, Aethlon Medical, Inc. (AEMD) trades at a EV/Sales of −2.7×. Over the past ten years it has ranged from −46.1× (December 2022) to 458× (January 2015); the current reading is higher than 27% of that period. That is below the Medical Devices industry median of 2.8× and below the Healthcare sector median of 3.6×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2023 −8.0× —
FY2022 18.4× 52.97%
FY2021 12.0× —
FY2020 −4.5× —
FY2019 34.5× 73.45%
FY2018 19.9× (36.21%)
FY2017 31.1× (9.60%)
FY2016 34.4× (61.55%)
FY2015 89.6× —

Quarterly newest first

Period EV/Sales Change
Mar 2023 −7.9× —
Mar 2022 18.4× (33.77%)
Dec 2021 27.7× (29.47%)
Sep 2021 39.3× 1.50%
18 more quarters

Against its own ten years

Low −46.1× High 458×
Ten-year median 10.0×
Current reading's percentile 27

EV/Sales against peers

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on AEMD